Ito Ryo, Kondo Yusuke, Winter Joachim, Hayashi Tomohiko, Nakano Miyo, Kajiyama Takatsugu, Nakano Masahiro, Kobayashi Yoshio
Department of Cardiovascular Medicine Chiba University Graduate School of Medicine Chiba Japan.
Department of Advanced Cardiorhythm Therapeutics Chiba University Graduate School of Medicine Chiba Japan.
J Arrhythm. 2019 Jan 16;35(2):311-313. doi: 10.1002/joa3.12152. eCollection 2019 Apr.
The subcutaneous implantable cardioverter defibrillator (S-ICD) system was developed for defibrillation therapy that does not affect the heart and vasculature. S-ICD is preferred over transvenous ICD for patients with a history of recurrent infection presenting with life-threatening rhythms. Patients with bradycardia pacing indications are excluded from S-ICD therapy, as S-ICD lacks the capability of defibrillation in this patient group. Implantation of an S-ICD with a leadless pacemaker (LP) was proposed to overcome this issue. We describe the first case of successful implantation of S-ICD and LP in a Japanese patient with a history of recurrent prosthetic valve endocarditis.
皮下植入式心律转复除颤器(S-ICD)系统是为不影响心脏和血管系统的除颤治疗而开发的。对于有反复感染史且出现危及生命节律的患者,S-ICD比经静脉ICD更受青睐。有心动过缓起搏指征的患者被排除在S-ICD治疗之外,因为S-ICD在该患者群体中缺乏除颤能力。有人提出植入带有无导线起搏器(LP)的S-ICD来克服这一问题。我们描述了首例在一名有反复人工瓣膜心内膜炎病史的日本患者中成功植入S-ICD和LP的病例。